{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T10:49:21Z","timestamp":1791715761266,"version":"4.3.4"},"reference-count":34,"publisher":"SAGE Publications","issue":"9","license":[{"start":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:00Z","timestamp":1783641600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"Alfasigma S.p.A."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Biotherapy and Radiopharmaceuticals"],"published-print":{"date-parts":[[2026,11,1]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>\n                      AvidinOX\n                      <jats:sup>\u2122<\/jats:sup>\n                      forms a long-lasting artificial receptor that supports effective\n                      <jats:italic toggle=\"yes\">in\u00a0vivo<\/jats:italic>\n                      binding of circulating biotinylated therapeutic\n                      <jats:sup>177<\/jats:sup>\n                      Lu-DOTA-biotin. We investigated the biodistribution and radiation dosimetry of\n                      <jats:sup>177<\/jats:sup>\n                      Lu-DOTA-biotin in patients with solid tumors following image-guided intratumoral AvidinOX administration.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      Three patients received intratumoral injections of AvidinOX and two cycles of intravenous administration of\n                      <jats:sup>177<\/jats:sup>\n                      Lu-DOTA-biotin over a period of 2 weeks. Multi-time-point whole-body planar and SPECT\/CT imaging was performed post infusion. Blood and urine samples were collected over 7 days, and organ radiation doses were estimated using the Medical Internal Radiation Dose methodology.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Sequential imaging demonstrated favorable tumor-to-background ratios and sustained uptake of\n                      <jats:sup>177<\/jats:sup>\n                      Lu-DOTA-biotin within the pretargeted lesions, confirming effective localization and prolonged retention. Most of the administered activity was excreted via urine within 4 h post infusion. The absorbed tumor radiation dose ranged from 3.96 to 50.37 Gy, while bone marrow (0.15\u20130.22 Gy) and kidney (0.66\u20131.84 Gy) doses remained below established safety thresholds. There were no serious adverse events.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>\n                      Intratumoral AvidinOX achieved effective and durable localization of\n                      <jats:sup>177<\/jats:sup>\n                      Lu-DOTA-biotin without exceeding the maximum allowable radiation absorbed dose to critical organs. These first-in-human dosimetric data provide quantitative insight into tumor retention, off-target exposure, and therapeutic potential across solid tumors, supporting the rational design of future radionuclide therapy trials.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10849785261465837","type":"journal-article","created":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T06:45:32Z","timestamp":1783752332000},"page":"782-793","source":"Crossref","is-referenced-by-count":0,"title":["Personalized Radionuclide Therapy via Avidin-Biotin Pretargeting: Biodistribution and Dosimetry of\n                    <sup>177<\/sup>\n                    Lu-DOTA-biotin with AvidinOX\n                    <sup>TM<\/sup>\n                    in Solid Tumors"],"prefix":"10.1177","volume":"41","author":[{"given":"Freddy","family":"Gonzalez","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6064-6837","authenticated-orcid":false,"given":"Vivek","family":"Subbiah","sequence":"additional","affiliation":[{"name":"Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA."},{"name":"Sarah Cannon Research Institute, Nashville, Tennessee, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Cheenu","family":"Kappadath","sequence":"additional","affiliation":[{"name":"Department of Imaging Physics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Martiniova","sequence":"additional","affiliation":[{"name":"Department of Imaging Physics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gera","family":"Santiago","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi","family":"Murthy","sequence":"additional","affiliation":[{"name":"Department of Diagnostic and Interventional Imaging, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"De Santis","sequence":"additional","affiliation":[{"name":"R&amp;D Department, Alfasigma S.p.A, Rome, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4659-5180","authenticated-orcid":false,"given":"Gregory C.","family":"Ravizzini","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,7,10]]},"reference":[{"key":"e_1_3_3_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2023.11.018"},{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107322"},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.263441"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-009-1260-4"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.3332\/ecancer.2010.166"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-006-0124-4"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1042\/bj0890599"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-1058"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1089\/cbr.2009.0738"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.1155\/2009\/921434"},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/0003-9861(64)90150-x"},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/11717"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/0022-1759(87)90120-7"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-7843.2011.00701.x"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.1089\/cbr.2015.1837"},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0021075"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.3389\/fchem.2023.1218670"},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/jmrs.227"},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.6089"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.108.057331"},{"issue":"2","key":"e_1_3_3_22_1","article-title":"Consolidated guidance about materials licenses","volume":"1","author":"Cook JHT","year":"2016","unstructured":"21.Cook JHT, , Juran B, et al. Consolidated guidance about materials licenses. NUREG-1556 2016;1(Rev. 2). Available from: https:\/\/wwwnrcgov\/docs\/ML1617\/ML16175A375pdf","journal-title":"NUREG-1556"},{"key":"e_1_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13550-018-0427-z"},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.112.107524"},{"key":"e_1_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.114.148437"},{"key":"e_1_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.15145"},{"key":"e_1_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.1177\/039463201202500126"},{"key":"e_1_3_3_28_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.2409"},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-009-1216-8"},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-015-3001-1"},{"key":"e_1_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.124.268903"},{"key":"e_1_3_3_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-015-3193-4"},{"key":"e_1_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.267023"},{"issue":"3","key":"e_1_3_3_34_1","first-page":"451","article-title":"Dosimetry-guided radioactive iodine treatment in patients with metastatic differentiated thyroid cancer: Largest safe dose using a risk-adapted approach","volume":"44","author":"Dorn R","year":"2003","unstructured":"33.Dorn R, , Kopp J, , Vogt H, et al. Dosimetry-guided radioactive iodine treatment in patients with metastatic differentiated thyroid cancer: Largest safe dose using a risk-adapted approach. J Nucl Med 2003;44(3):451\u2013456.","journal-title":"J Nucl Med"},{"key":"e_1_3_3_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-017-3678-4"}],"container-title":["Cancer Biotherapy and Radiopharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10849785261465837","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10849785261465837","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10849785261465837","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T10:20:18Z","timestamp":1791714018000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10849785261465837"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,10]]},"references-count":34,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,11,1]]}},"alternative-id":["10.1177\/10849785261465837"],"URL":"https:\/\/doi.org\/10.1177\/10849785261465837","relation":{},"ISSN":["1084-9785","1557-8852"],"issn-type":[{"value":"1084-9785","type":"print"},{"value":"1557-8852","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,10]]}}}